A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
POXEL operates in the Biotechnology industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | 16M | - |
| Net Income | -20M | -20M | -38M | -33M | -28M | -37M |
| EPS | $-0.41 | $-0.41 | $-1.14 | $-1.14 | $-0.98 | $-1.33 |
| Free Cash Flow | -10M | -10M | -15M | -23M | -20M | -30M |
| ROIC | -18.5% | -18.5% | -471.1% | -49.8% | -295.1% | -300.2% |
| Gross Margin | - | - | - | - | 99.6% | - |
| Debt/Equity | 0.00 | - | - | - | 3.67 | 0.78 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -3.8M | -3.8M | -31M | -23M | -27M | -34M |
| Operating Margin | 0.0% | - | - | - | -167.7% | - |
| ROE | 0.0% | - | - | - | -137.6% | -117.6% |
| Shares Outstanding | 48M | 48M | 33M | 29M | 29M | 27M |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | N/A | 16M | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | 99.6% | N/A | N/A | N/A | N/A |
| R&D | -34M | -32M | -15M | -23M | -1.1M | -1.1M |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -34M | -27M | -23M | -31M | -3.8M | -3.8M |
| Op. Margin | N/A | -167.7% | N/A | N/A | N/A | 0.0% |
| Net Income | -37M | -28M | -33M | -38M | -20M | -20M |
| Net Margin | N/A | -177.4% | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | N/M | N/M | -49.8% | N/M | -18.5% | -18.5% |
| ROE | -117.6% | -137.6% | N/A | N/A | N/A | 0.0% |
| ROA | -48.9% | -40.2% | -65.3% | -182.3% | -185.1% | -122.6% |
| Cash Flow | ||||||
| Op. Cash Flow | -30M | -20M | -23M | -15M | -10M | -10M |
| Free Cash Flow | -30M | -20M | -23M | -15M | -10M | -10M |
| Owner Earnings | -33M | -25M | -26M | -16M | -10M | -10M |
| CapEx | 270K | 33K | 12K | 0 | 0 | 0 |
| Maint. CapEx | 0 | 0 | 0 | 0 | 0 | 0 |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | 0 |
| D&A | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 279K | 46K | 69K | 20K | 24K | 24K |
| Buyback Yield | 0.1% | 0.0% | 0.2% | 0.1% | 0.3% | 0.2% |
| Stock-Based Comp | 3.2M | 5.4M | 3.0M | 486K | 85K | 85K |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | -22M | -2.6M | 13M | 42M | 55M | -4.0M |
| Cash & Equiv. | 46M | 38M | 14M | 2.5M | 4.0M | 4.0M |
| Long-Term Debt | 24M | 36M | 27M | 44M | 59M | 59M |
| Debt/Equity | 0.78 | 3.67 | N/A | N/A | N/A | 0.00 |
| Interest Coverage | -17.3 | -7.6 | -2.2 | -4.7 | -0.2 | -0.2 |
| Equity | 31M | 9.7M | -19M | -53M | -64M | -64M |
| Total Assets | 75M | 65M | 37M | 5.2M | 16M | 16M |
| Total Liabilities | 44M | 55M | N/A | N/A | N/A | N/A |
| Intangibles | 19M | N/A | N/A | 11K | 2K | 2K |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A | N/A |
| Working Capital | 34M | 24M | -11M | -9.5M | -4.4M | -4.4M |
| Current Assets | 53M | 43M | 17M | 4.9M | 16M | 16M |
| Current Liabilities | 19M | 19M | 29M | 14M | 20M | 20M |
| Per Share Data | ||||||
| EPS | -1.33 | -0.98 | -1.14 | -1.14 | -0.41 | -0.41 |
| Owner EPS | -1.19 | -0.89 | -0.89 | -0.47 | -0.22 | -0.22 |
| Book Value | 1.13 | 0.34 | -0.66 | -1.59 | -1.32 | -1.32 |
| Cash Flow/Share | -1.08 | -0.70 | -0.79 | -0.45 | -0.21 | -0.41 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 27.4M | 28.6M | 29.1M | 33.4M | 48.2M | 48.2M |
| Valuation | ||||||
| P/E Ratio | -6.1 | -5.9 | -1.0 | -0.5 | -0.4 | -0.6 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 7.2 | 16.9 | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | 10.4 | N/A | N/A | N/A | N/A |
| FCF Yield | -13.4% | -12.2% | -71.1% | -74.5% | -145.8% | -85.3% |
| Market Cap | 222M | 164M | 32M | 20M | 7.0M | 12M |
| Avg. Price | 8.70 | 7.47 | 2.43 | 0.68 | 0.51 | 0.25 |
| Year-End Price | 8.11 | 5.73 | 1.11 | 0.61 | 0.15 | 0.25 |
POXEL passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 99.6%. Total shareholder yield (buybacks) is 0.2%.
POXEL (POXEL-PA) has a 5-year average return on invested capital (ROIC) of -34.2%. This is below average and may indicate limited pricing power.
POXEL (POXEL-PA) has a market capitalization of $12M. It is classified as a small-cap stock.
POXEL (POXEL-PA) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.20%.
POXEL (POXEL-PA) operates in the Biotechnology industry, within the Healthcare sector.
POXEL (POXEL-PA) generated $-10 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
POXEL (POXEL-PA) reported earnings per share (EPS) of $-0.41 in its most recent fiscal year.
POXEL (POXEL-PA) has a 5-year average gross margin of 99.6%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 5 years of financial data for POXEL (POXEL-PA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
POXEL (POXEL-PA) has a book value per share of $-1.32, based on its most recent annual SEC filing.